South San Francisco, CA
Mirvie is redefining pregnancy health by developing the first early detection RNA test to address pregnancy complications which impact 45 million women globally.
mirvie.comThese are collections Mirvie is a part of. Click on the collection name to view similar companies.
Series C
$23,702,346
Grant
$4,600,000
Series B
$45,000,000
Debt Financing
$15,000,000
Series A
$5,800,000
0 out of 5 stars
Based on 0 reviews
Worked here? Share your experience. Help others decide if this company is right for them. Write a review on Mirvie.